Innovent Starts China Trials of Bi-Specific Wet AMD Treatment

Innovent Biologics has dosed the first patient in a China Phase I trial of IBI302, a novel bi-specific fusion protein aimed at treating wet age-related macular degeneration (wet AMD). IBI302 targets vascular endothelial growth factor A (VEGF-A), the current standard of care, along with complement proteins that regulate the production of VEGF. Michael Yu, Founder and CEO of Innovent, said IBI302 may improve wet AMD treatment, offering a less-frequent dosing regimen and better long-term outcomes because the candidate treats causes rather than effects of the disease. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //